Filing Details

Accession Number:
0001181431-13-028821
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-05-17 19:03:14
Reporting Period:
2013-05-07
Filing Date:
2013-05-17
Accepted Time:
2013-05-17 19:03:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
861838 Idera Pharmaceuticals Inc. IDRA Biological Products, (No Disgnostic Substances) (2836) 043072298
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1193366 El Youssef Zein Pillar Invest Offshore Sal, Starko Ctr,
Bloc B, 3Rd Floor, Omar Daouk Street
Beirut M8 2020-3313
Yes No Yes No
1534425 Pillar Pharmaceuticals I Lp Pillar Invest Offshore Sal, Starko Ctr,
Bloc B, 3Rd Floor, Omar Daouk Street
Beirut M8 2020-3313
Yes No Yes No
1534428 Pillar Invest Corp C/O Idera Pharmaceuticals, Inc.
167 Sidney Street
Cambridge MA 02139
Yes No Yes No
1562069 Pillar Pharmaceuticals Ii, L.p. Pillar Invest Offshore Sal, Starko Ctr,
Bloc B, 3Rd Floor, Omar Daouk Street
Beirut M8 2020-3313
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-05-07 2,600,000 $0.00 0 No 4 P Indirect See Footnote
Common Stock Acquisiton 2013-05-07 2,400,000 $0.00 0 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrants Acquisiton 2013-05-07 1,000,000 $0.00 1,000,000 $0.61
Common Stock Warrants Acquisiton 2013-05-07 575,758 $0.00 575,758 $0.79
Common Stock Warrants Acquisiton 2013-05-07 313,341 $0.00 313,341 $0.79
Common Stock Warrants Acquisiton 2013-05-07 110,901 $0.00 110,901 $0.79
Common Stock Warrants Acquisiton 2013-05-07 2,600,000 $0.00 2,600,000 $0.47
Common Stock Warrants Acquisiton 2013-05-07 2,400,000 $0.00 2,400,000 $0.47
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2013-05-07 2018-05-07 No 4 A Indirect
0 2013-05-07 2014-06-01 No 4 A Indirect
0 2013-05-07 2014-06-01 No 4 A Indirect
0 2013-05-07 2014-06-01 No 4 A Indirect
0 2013-05-07 2018-05-07 No 4 P Indirect
0 2013-05-07 2018-05-07 No 4 P Indirect
Footnotes
  1. On May 7, 2013, upon the consummation of a public offering of the Issuer (the "Offering"), Pillar Pharmaceuticals I, L.P. ("Pillar I"), of which Pillar Invest Corporation ("Pillar GP") is the general partner, acquired, directly from the Issuer, warrants to purchase up to 1,575,758 shares of common stock (the "Pillar I Shares") of the Issuer. Pillar GP disclaims Section 16 beneficial ownership of the Pillar I Shares and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar I.
  2. On May 7, 2013, upon the consummation of the Offering, Pillar Pharmaceuticals II, L.P. ("Pillar II"), of which Pillar GP is the general partner, acquired, directly from the Issuer, warrants to purchase up to 313,341 shares of common stock (the "Pillar II Shares") of the Issuer. Pillar GP disclaims Section 16 beneficial ownership of the Pillar II Shares and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar II.
  3. On May 7, 2013, upon the consummation of the Offering, Participations Besancon ("Besancon"), a fund advised by Pillar GP, acquired, directly from the Issuer, warrants to purchase up to 110,901 shares of common stock (the "Besancon Warrants"). Pillar GP disclaims Section 16 beneficial ownership of the Besancon Warrants and this report shall not be deemed an admission that Pillar GP is the beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, resulting from fees payable to Pillar GP in its capacity as investment advisor to Besancon.
  4. Youssef El Zein is a director and controlling stockholder of Pillar GP and serves as the representative of a Pillar I, Pillar II, Pillar III and Pillar GP on the Issuer's board of directors. Mr. El Zein disclaims Section 16 beneficial ownership of the Pillar I Shares, Pillar II Shares, Pillar III Shares, Besancon Warrants and Besancon Shares and this report shall not be deemed an admission that he is the beneficial owners of any such securities, except to the extent of his pecuniary interest therein, if any, by virtue of his ownership interest in Pillar GP. As of the date hereof, Mr. El Zein owns directly 586,101 shares of common stock of the Issuer.
  5. On May 7, 2013, upon the consummation of the Offering, Pillar Pharmaceuticals III, L.P. ("Pillar III"), of which Pillar GP is the general partner, acquired, in the Offering, 2,600,000 shares of common stock and warrants to purchase up to 2,600,000 shares of common stock (the "Pillar III Shares") of the Issuer. Pillar GP disclaims Section 16 beneficial ownership of the Pillar III Shares and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar III. As of the date hereof, Pillar III owns directly 2,600,000 shares of common stock of the Issuer.
  6. On May 7, 2013, upon the consummation of the Offering, Besancon acquired, in the Offering, 2,400,000 shares of common stock and warrants to purchase up to 2,400,000 shares of common stock (the "Besancon Shares"). Pillar GP also disclaims Section 16 beneficial ownership of the Besancon Shares and this report shall not be deemed an admission that Pillar GP is the beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, resulting from fees payable to Pillar GP in its capacity as investment advisor to Besancon. As of the date hereof, Besancon owns directly 2,400,000 shares of common stock of the Issuer.